<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03054155</url>
  </required_header>
  <id_info>
    <org_study_id>120116M1F</org_study_id>
    <nct_id>NCT03054155</nct_id>
  </id_info>
  <brief_title>Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser</brief_title>
  <official_title>Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with bilateral hidradenitis in the axilla, groin and/or inframammary will be treated
      on one side with the Alexandrite hair removal laser. The other side will serve as the
      control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with bilateral disease will be chosen to participate in the study. Patients will be
      advised to discontinue any prior systemic HS treatments two weeks before their first laser
      session as a wash out period. One side of the patient will be chosen as the treatment side,
      the other as an intrinsic control. Each participant will have a total of 4 treatments with
      the laser, one treatment per month over the duration of 4 months. Patients will then
      participate in a follow-up clinic visit two months after completion of their last treatment.
      In between laser sessions, participants will be allowed to use benzoyl peroxide 10% wash as a
      skin cleanser and clindamycin 1% solution or lotion as a topical therapy, both twice daily to
      the treatment and control areas. At each visit, photographs will be taken of the lesions to
      monitor progression and to serve as a comparison to the control side. The treatment side will
      be treated with the laser and adjusted according to skin type as follows:

      Skin type I-II (Fair Caucasian): Fluence: 30J/cm2 Skin type III (Darker Caucasian, light
      Asian): Fluence: 25 J/cm2 Skin type IV (Mediterranean, Asian, Latin): Fluence: 18 J/cm2 Skin
      type V (Light skinned black, Darker mediterranean): Fluence: 16J/cm2 Skin type VI (Dark
      skinned black): Fluence 14 J/cm2

      A spot size of 12 mm and a cryogen spray delay of 50/50 will be used for all treated
      patients. The treatment area will not exceed 15cm x 15cm. If the patient cannot tolerate
      treatment with the Alexandrite laser, the patient will be terminated from the study.
      Following each treatment session, the patient will be given an ice pack to reduce any
      discomfort the patient may experience as a result of treatment with the laser. Clinical
      evaluation and photographs will determine improvement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>For each patient, one side of the body will serve as the treatment side and the other side as the control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HS-LASI</measure>
    <time_frame>Monthly for 4 months, then once 2 months later(6 months total)</time_frame>
    <description>Change in Hidradenitis Suppurativa Lesion, Area, and Severity Index Score from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HiSCR</measure>
    <time_frame>Monthly for 4 months, then once 2 months later(6 months total)</time_frame>
    <description>Change in Hidradenitis Suppurativa Clinical Response Scale from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alexandrite Laser</intervention_name>
    <description>Alexandrite 755nm hair removal laser</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65

          -  Patients with Hidradenitis Suppurativa with bilateral and symmetric disease with one
             or more anatomic sites of involvement.

        Exclusion Criteria:

          -  Pregnant patients or patients planning to get pregnant during the time of the study

          -  Patients on systemic treatment for Hidradenitis Suppurativa

          -  Patients with photosensitivity disorders

          -  Patients unable to tolerate the laser treatments

          -  Intake of a photosensitive medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Steven D Daveluy, MD</last_name>
    <phone>3134297854</phone>
    <email>sdaveluy@med.wayne.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emma Reaves</last_name>
    <phone>3134297845</phone>
    <email>az3432@wayne.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wayne State University Physician Group Dermatology</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven D Daveluy, MD</last_name>
      <phone>313-429-7854</phone>
      <email>sdaveluy@med.wayne.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emma Reaves</last_name>
      <phone>3134297845</phone>
      <email>az3432@wayne.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven D Daveluy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Ward, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristin Totoraitis, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tierney E, Mahmoud BH, Hexsel C, Ozog D, Hamzavi I. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg. 2009 Aug;35(8):1188-98. doi: 10.1111/j.1524-4725.2009.01214.x. Epub 2009 May 12.</citation>
    <PMID>19438670</PMID>
  </reference>
  <reference>
    <citation>Mahmoud BH, Tierney E, Hexsel CL, Pui J, Ozog DM, Hamzavi IH. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium-aluminium-garnet laser. J Am Acad Dermatol. 2010 Apr;62(4):637-45. doi: 10.1016/j.jaad.2009.07.048.</citation>
    <PMID>20227579</PMID>
  </reference>
  <reference>
    <citation>Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, Teixeira HD, Jemec GB. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016 Jun;30(6):989-94. doi: 10.1111/jdv.13216. Epub 2015 Jul 22.</citation>
    <PMID>26201313</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>February 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2017</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Steven Daveluy</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>hidradenitis suppurativa</keyword>
  <keyword>hidradenitis</keyword>
  <keyword>laser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis</mesh_term>
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

